Although C3 is the main driver of the disease, C5aR blockage is suggested to add substantial benefit for C3 glomerulopathy patients, which is supported by positive findings with eculizumab in prospective clinical trials (99, 100, 102, 103). The gene discussed is C3; the disease is glomerular disorder.